CFO MossとCEO TesiはINmune Bioの株を買い,その間,同社は負の利益と機関的な関心の増加を報告し,Scotiabankは22ドルの目標価格を設定した. CFO Moss and CEO Tesi of INmune Bio purchased shares, while the firm reported negative earnings and increased institutional interest, with Scotiabank setting a $22 target price.

CFO David J. MossとCEO Raymond J. Tesiは最近,INmune Bio (NASDAQ: INMB) の株式を購入し,Mossは49,062ドルの価値とTesiは98,124ドルの価値を獲得し,それぞれ総所有権を127万株と155万株に増加させた. CFO David J. Moss and CEO Raymond J. Tesi of INmune Bio (NASDAQ: INMB) recently bought shares, with Moss acquiring $49,062 worth and Tesi $98,124, raising their total ownership to 1.27 million and 1.55 million shares, respectively. 臨床段階の免疫学会社は 癌と慢性炎症の治療に重点を置いています 収入はマイナスで 機関的な関心が高まっています The clinical-stage immunology firm, focusing on treatments for cancers and chronic inflammation, reported negative earnings and has seen increasing institutional interest. スコティアバンクが 株価を22ドルに設定した Scotiabank set a target price of $22 for the stock.